Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
stavudine, efavirenz, lamivudine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| stavudine, efavirenz, lamivudine | DRUG | - |
Inclusion Criteria: * Completed d4T studies AI455-096 or AI455-099 * Have demonstrated compliance with the study medication and treatment visits * Provide written informed consent * Agree to use a barrier method of birth control (such as condoms) during the study * Have a negative pregnancy test wi...
Top 20 of 28 competitors
Stavudine is an investigational small molecule being studied for the treatment of HIV Infections and AIDS Dementia Complex. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 3 clinical development. Stavudine is not approved and remains under investigation for these indications.
Stavudine is a small molecule being studied for HIV Infections and AIDS Dementia Complex. Its molecular target has not been disclosed in the available information, so its specific mechanism of action is not described here. The drug is in Phase 3 clinical trials for these infectious disease indications.
Stavudine is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting Phase 3 clinical trials for Stavudine in HIV Infections and AIDS Dementia Complex. Stavudine is an investigational small molecule and has not been approved for these uses.
Stavudine is in Phase 3 clinical development. It is being studied for HIV Infections and AIDS Dementia Complex, with two completed Phase 3 trials. Stavudine is investigational and not yet approved, as it remains in clinical trials for these indications.
Stavudine has two completed Phase 3 trials: NCT00002246, which evaluated stavudine (d4T) for AIDS Dementia Complex with 20 participants in the US, Australia, and UK, and NCT00116298, a rollover study for Zerit (stavudine) ER with 900 participants across multiple countries. Both trials are completed.
Stavudine is also known as Zerit, as referenced in the clinical trial NCT00116298, which is titled 'Rollover Study for Zerit (Stavudine) ER Studies'. This indicates that Zerit is a brand name for stavudine. Stavudine is being developed by Bristol-Myers Squibb Company for HIV Infections and AIDS Dementia Complex.